Monday, 4 July, 2022

DGDA cancels registration of eight drugs

The Directorate General of Drug Administration (DGDA) has cancelled the registrations of eight drugs in the country.

"We have cancelled the registration of four human drugs and four veterinary drugs. We will issue notice to the drug manufacturing and marketing companies to take a step in this regard," Ayub Hossain, director of the DGDA, told the Daily Sun.

According to an office order of DGDA, the four human drugs are Rebeprazole Sodium Enteric Coated Pellets 8.5% w/w Ph. Grade 235.294mg (Contains Rebeprazole Sodium BP 20mg Capsule), Bromelain 50mg+Trypsin 1 mg tablet (Bromelain USP 50mg+Trypsin BP 1mg), Astaxanthin INN 2mg (soft gelatin capsule and powder filled hard gelatincapsule) and Astaxanthin INN 4mg (soft gelatin capsule and powder-filled hard gelatin capsule).

The four veterinary drugs are Ceftriaxone (as Sodium) vet injection (Ceftriaxone 0.25 g USP/vial as sterile Ceftriaxone Sodium USP), Levofloxacin Hemihydrate 10.25mg equivalent to Levofloxacin 10gm/100ml solution (10%) oral solution, Ketoprofen, and Colistin (Oral Solution and Injectible form).

The DGDA's Drug Control Committee took the decision at its 253rd meeting on Monday.

"Their registrations have been cancelled as some confusion arose about the safety of these medicines. The veterinary drugs can cause antimicrobial resistance in humans," said the officer.